Get the Stockscreener App
8.08
1.34%
-0.11
Immunitybio Inc stock is traded at $8.08, with a volume of 4.32M.
It is down -1.34% in the last 24 hours and up +16.26% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.19
Open:
$8.08
24h Volume:
4.32M
Relative Volume:
0.43
Market Cap:
$8.56B
Revenue:
$140.98M
Net Income/Loss:
$-854.60M
P/E Ratio:
-9.4614
EPS:
-0.854
Net Cash Flow:
$-299.31M
1W Performance:
+0.37%
1M Performance:
+16.26%
6M Performance:
-10.22%
1Y Performance:
+238.08%
1-Day Range:
$8.01
$8.24
1-Week Range:
$7.73
$8.28
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.08 | 8.31B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. Tokenized Stock (Robinhood) to United States Dollar Price Today | Live IBRX to USD Converter & Exchange Rate - CryptoRank
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
2026-09-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation | NDAQ:IBRX | Press Release - Stockhouse
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - Stocktwits
IBRX Stock Slips Overnight: Founder Teases Turkey Push, Says AI Cancer Cell Robot Is ‘Almost There’ - Stocktwits
ImmunityBio, Inc. Tokenized Stock (Robinhood) Exchanges IBRX Markets | Buy & Sell & Trade - CryptoRank
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report? - finance.yahoo.com
ImmunityBio: None Of The Moonshots Is Priced In (NASDAQ:IBRX) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Investors to Connect - ACCESS Newswire
IBRX to IDR: ImmunityBio, Inc. • Robinhood Token Price in Indonesian Rupiah - CoinGecko
IBRX|Immunitybio Inc|Price:7.835|Chg%:-0.035 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Connect - ACCESS Newswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ImmunityBio, Inc. Tokenized Stock (Robinhood) Closing Price (USD)Quarterly - CryptoRank
ImmunityBio Stock Short Interest Falls to 31.8% - Quiver Quantitative
ImmunityBio: ANKTIVA Is Real, The Valuation Isn't (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer - Eastern Progress
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitContact Kessler Topaz Meltzer & Check, LLP - Morningstar
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio (NASDAQ:IBRX): What Could Shape Its Next Move? - Kalkine Media
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patrick Soon-Shiong to Thomas Ichim: Thanks for Sharing Important Difference Between Il-2 and Il-15 - Oncodaily
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Class A - The National Law Review
ImmunityBio (IBRX) Shares Moved, What Is Behind The Fresh Attention? - Sahm
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)? - simplywall.st
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
ImmunityBio, Inc. (IBRX) Investor Outlook: Exploring A 70% Upside Potential - DirectorsTalk Interviews
Jim Yong Kim Joins ImmunityBio as Vice Chairman - Oncodaily
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - bybit.com
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
ImmunityBio appoints Jim Yong Kim as vice chairman - Investing.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - ImmunityBio
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next - webull.com
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken In - The National Law Review
Analysts Have Been Trimming Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target After Its Latest Report - 富途牛牛
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - finance.yahoo.com
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses - Yahoo Finance
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake - Stock Titan
Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cohen Cheryl | Director |
Jul 02 '26 |
Sale |
9.50 |
131,210 |
1,246,941 |
125,386 |
| Selecky Christobel | Director |
Jul 01 '26 |
Option Exercise |
2.99 |
159,478 |
476,489 |
159,478 |
| Selecky Christobel | Director |
Jul 01 '26 |
Sale |
9.02 |
159,478 |
1,439,066 |
0 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):